Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZURE-1: BJT-778 vs delayed treatment in chronic hepatitis delta infection
2024-519063-18-00Phase 3Authorised
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of brelovitug in hepatitis D (HDV) (2 arms), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoint: Primary composite endpoint of virologic response and ALT normalization. Planned start Jun 2025; status: authorised.
02
Drugs
brelovitug
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on 2024-519063-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519063-18-00.